CLINICAL_TRIALS
trial_result
· 2016-12-23
Clinical Trial Update: BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) [Phase 2, Phase 3]
Summary
Clinical trial update for Tonix's sublingual TNX-102 SL in fibromyalgia reports completion and posting of BESTFIT Phase 2/Phase 3 results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: Primary Fibromyalgia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-12-23